Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Paediatric HIV infection is a growing health challenge worldwide, with an estimated 1500 new infections every day. In developed countries, well established prevention programmes keep mother-to-child transmission rates at less than 2%. However, in developing countries, where transmission rates are 25-40%, interventions are available to only 5-10% of women. Children with untreated natural infection progress rapidly to disease, especially in resource-poor settings where mortality is greater than 50% by 2 years of age. As in adult infection, antiretroviral therapy has the potential to rewrite the natural history of HIV, but is accessible only to a small number of children needing therapy. We focus on the clinical and immunological features of HIV that are specific to paediatric infection, and the formidable challenges ahead to ensure that all children worldwide have access to interventions that have proved successful in developed countries.

Original publication

DOI

10.1016/S0140-6736(07)61051-4

Type

Journal article

Journal

Lancet

Publication Date

07/07/2007

Volume

370

Pages

68 - 80

Keywords

Antiretroviral Therapy, Highly Active, Child, Preschool, HIV Infections, Humans, Infant, Infant Mortality, Infant, Newborn, Infectious Disease Transmission, Vertical, Pediatrics